Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

In Therapy-Related AML, p53 Mutations Already Exist

December 11, 2013
By Anna Azvolinsky
Article
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

In a study presented at the 2013 ASH meeting, researchers showed evidence that p53 mutations are already present in patients who develop treatment-related MDS and AML, results which could help identify high-risk patients prior to cytotoxic therapy.

Mutations in the tumor suppressor p53 are thought to arise in hematopoietic stem cells after exposure to chemotherapy and radiotherapy, causing therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), a cancer of the blood and bone marrow.

But in a surprising new finding that reverses this hypothesis, researchers now provide evidence that therapy-related AML actually arises due to the selection of pre-existing hematopoietic stem cells that harbor p53 mutations. Hematopoietic stem cells may acquire deleterious p53 mutations as a result of the normal aging process and are likely selected in the context of cytotoxic therapies, such as chemotherapy and radiation therapy.

The study results were presented at the plenary session of the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition, held in New Orleans.

“This new model explains many of the clinical features observed in therapy-induced AML,” said study presenter Terrence Neal Wong, MD, PhD, of Washington University in St. Louis, during his presentation. “This early loss of p53 may provide a mechanism for the resistance to chemotherapy and poor survival in these patients.”

AML is an aggressive malignancy of the bone marrow, characterized by a high relapse rate and resistance to chemotherapy agents, particularly for therapy-related AML. “Therapy-related myeloid malignancies are among the most feared long-term consequences of exposure to chemotherapy or radiation,” said Benjamin L. Ebert, MD, PhD, of the Brigham and Women’s Hospital and Harvard Medical School in Boston, who introduced the plenary presentation.

Therapy-related AML generally develops months or years after exposure to either radiation or chemotherapy. This type of blood disorder is characterized by a high incidence of p53 mutations compared with de novo AML, as well as a complex karyotype and poor overall survival.

The long-standing theory for the development of therapy-related AML is that the accumulation of mutations, including in key driver genes, as a result of exposure to cytotoxic therapy ultimately leads to clonal expansion and AML. But one observation was not consistent with this theory: Therapy-related AML does not have a particularly high mutation burden compared with de novo AML, which would be expected as a result of exposure to chemotherapy or radiotherapy.

Wong showed evidence that p53 mutations are present in the existing pool of hematopoietic stem cells prior to cytotoxic therapy exposure. This population of cells has a selective advantage and expands following therapy and acquires somatic mutations and karyotypic complexities that can ultimately lead to therapy-related AML.

Wong and colleagues expanded their initial analysis of 22 therapy-related AML and 49 de novo AML cases to include an additional 89 patients with therapy-related AML or MDS, finding that p53 mutations occurred in 31.5% of cases and was the only mutation that occurred at a higher frequency compared with de novo AML or MDS.

The study authors used next-generation whole genome sequencing that is able to detect rare cell subclones on paired bone marrow and skin specimens from therapy-related AML patients at diagnosis. They were able to show several cases where the driver p53 mutation was present prior to the emergence of other somatic driver mutations and other cytogenic abnormalities, and treatment exposure.

Using bone marrow chimeras, Wong showed that the heterozygous loss of p53 results in a competitive advantage following chemotherapy but not if the cells are not exposed to cytotoxic therapy. An early acquisition of a p53 mutation in a founding hematopoietic stem cell clone likely contributes to later AML development following cytotoxic therapy.

Mutations of p53 are particularly common in therapy-related diseases, including hematopoietic cancers. The gene plays a key role in response to cytotoxic-based therapies and an essential role in maintaining genomic stability.

This study result could help identify patients at high risk for therapy-related AML by monitoring patients and identifying hematopoietic stem cells with existing p53 mutations prior to cytotoxic therapy, said Ebert during his presentation. Additionally, those patients who have received cytotoxic therapy could be monitored for p53-mutated clones.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content
Advertisement

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

Kristi Rosa
July 10th 2025
Article

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups

Kristi Rosa
July 9th 2025
Article

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.


Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Related Content
Advertisement

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

Kristi Rosa
July 10th 2025
Article

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups

Kristi Rosa
July 9th 2025
Article

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.


Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.